Stay updated with breaking news from Base Editing. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
As the annual J.P. Morgan HealthCare Conference kicked off Monday, two pharma giants unveiled deals that give them access to in-vivo gene editing technologies. Pfizer is teaming up with Beam Therapeutics to develop new base-editing therapies while Bayer hopes to develop new medicines with the in-vivo CRISPR editing tools of Mammoth Biosciences.
Company On-track to Submit First IND for BEAM-101 in the Second Half of 2021 Continued Progress Across Base Editing Portfolio, Including Initiation of...
For growth investors seeking disruptive exposure in the healthcare sector, genomics is often a favored destination.
CRISPR 2.0: Base Editing in the Groove A series of exciting preclinical and animal model results show that base editing is making rapid strides toward the clinic March 4, 2021 Researchers from the Broad Institute, the NIH, and Vanderbilt University have used an adenine base editor (ABE) to treat progeria in mice. Correcting the mutation that causes progeria led to strong symptom reduction and longer lifespan. An ABE is shown here bound to a guide RNA and a targeted piece of DNA. [Aditya Raguram, Liu Laboratory, Broad Institute] Share A reasonable idea, suggests Sekar Kathiresan, MD, co-founde...
Luke Koblan sat at his desk, staring at some data. Excited but baffled, the grad student thought, there’s no way those numbers could be right. He shared the results with his boss, Professor David Liu, and today, that data has spurred a team of scientists from the Broad Institute of MIT and Harvard (including Koblan and Liu), the National Institutes of Health, and Vanderbilt University Medical Center to achieve an almost unbelievable leap for the CRISPR gene-editing tool known as base editing, moving the technology a critical step closer to being a treatment for progeria, a deadly premature ...